{"entity":{"type":"insider","cik":"0001380841","url":"/insider/0001380841","json_url":"/insider/0001380841.json","name":"Shue Youe Kong","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":13,"n_filings":5,"first":"2007-08-13","last":"2009-12-02","span_basis":"filed_date"},"name_variants":[{"name":"Shue Youe Kong","source":"filing","n_filings":5,"first_seen":"2007-08-13","last_seen":"2009-12-02"}],"transactions":[{"id":5620749,"accession":"0001142576-09-000032","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001142576-09-000032","line_url":"/filing/0001142576-09-000032#line-4","is_derivative":false,"issuer_cik":"0001142576","issuer_name":"OPTIMER PHARMACEUTICALS INC","issuer_ticker":"OPTR","issuer_name_source":null,"issuer_url":"/issuer/0001142576","owner_cik":"0001380841","owner_name":"Shue Youe Kong","owner_url":"/insider/0001380841","role":"Officer (VP, Clinical Development)","officer_title":"VP, Clinical Development","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":1000.0,"shares_display":"1,000","price_per_share":10.96,"price_display":"10.96","price_state":"stated","total_value":10960.0,"total_display":"10,960.00","shares_owned_after":81648.0,"shares_owned_after_display":"81,648","ownership_form":"D","is_10b5_1":null,"transaction_date":"2009-12-02","filed_date":"2009-12-02","scope":"insider"},{"id":5620748,"accession":"0001142576-09-000032","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001142576-09-000032","line_url":"/filing/0001142576-09-000032#line-3","is_derivative":false,"issuer_cik":"0001142576","issuer_name":"OPTIMER PHARMACEUTICALS INC","issuer_ticker":"OPTR","issuer_name_source":null,"issuer_url":"/issuer/0001142576","owner_cik":"0001380841","owner_name":"Shue Youe Kong","owner_url":"/insider/0001380841","role":"Officer (VP, Clinical Development)","officer_title":"VP, Clinical Development","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":500.0,"shares_display":"500","price_per_share":10.9,"price_display":"10.90","price_state":"stated","total_value":5450.0,"total_display":"5,450.00","shares_owned_after":82148.0,"shares_owned_after_display":"82,148","ownership_form":"D","is_10b5_1":null,"transaction_date":"2009-12-02","filed_date":"2009-12-02","scope":"insider"},{"id":5620747,"accession":"0001142576-09-000032","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001142576-09-000032","line_url":"/filing/0001142576-09-000032#line-2","is_derivative":false,"issuer_cik":"0001142576","issuer_name":"OPTIMER PHARMACEUTICALS INC","issuer_ticker":"OPTR","issuer_name_source":null,"issuer_url":"/issuer/0001142576","owner_cik":"0001380841","owner_name":"Shue Youe Kong","owner_url":"/insider/0001380841","role":"Officer (VP, Clinical Development)","officer_title":"VP, Clinical Development","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":500.0,"shares_display":"500","price_per_share":10.89,"price_display":"10.89","price_state":"stated","total_value":5445.0,"total_display":"5,445.00","shares_owned_after":82648.0,"shares_owned_after_display":"82,648","ownership_form":"D","is_10b5_1":null,"transaction_date":"2009-12-02","filed_date":"2009-12-02","scope":"insider"},{"id":5620746,"accession":"0001142576-09-000032","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001142576-09-000032","line_url":"/filing/0001142576-09-000032#line-1","is_derivative":false,"issuer_cik":"0001142576","issuer_name":"OPTIMER PHARMACEUTICALS INC","issuer_ticker":"OPTR","issuer_name_source":null,"issuer_url":"/issuer/0001142576","owner_cik":"0001380841","owner_name":"Shue Youe Kong","owner_url":"/insider/0001380841","role":"Officer (VP, Clinical Development)","officer_title":"VP, Clinical Development","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":1000.0,"shares_display":"1,000","price_per_share":11.1,"price_display":"11.10","price_state":"stated","total_value":11100.0,"total_display":"11,100.00","shares_owned_after":80648.0,"shares_owned_after_display":"80,648","ownership_form":"D","is_10b5_1":null,"transaction_date":"2009-12-01","filed_date":"2009-12-02","scope":"insider"},{"id":3806733,"accession":"0001142576-08-000021","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001142576-08-000021","line_url":"/filing/0001142576-08-000021#line-1","is_derivative":false,"issuer_cik":"0001142576","issuer_name":"OPTIMER PHARMACEUTICALS INC","issuer_ticker":"OPTR","issuer_name_source":null,"issuer_url":"/issuer/0001142576","owner_cik":"0001380841","owner_name":"Shue Youe Kong","owner_url":"/insider/0001380841","role":"Officer (VP Clinical Development)","officer_title":"VP Clinical Development","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":1699.0,"shares_display":"1,699","price_per_share":6.1795,"price_display":"6.18","price_state":"stated","total_value":10498.9705,"total_display":"10,498.97","shares_owned_after":77061.0,"shares_owned_after_display":"77,061","ownership_form":"D","is_10b5_1":null,"transaction_date":"2008-11-17","filed_date":"2008-12-22","scope":"insider"},{"id":3445270,"accession":"0001142576-08-000015","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001142576-08-000015","line_url":"/filing/0001142576-08-000015#line-1","is_derivative":false,"issuer_cik":"0001142576","issuer_name":"OPTIMER PHARMACEUTICALS INC","issuer_ticker":"OPTR","issuer_name_source":null,"issuer_url":"/issuer/0001142576","owner_cik":"0001380841","owner_name":"Shue Youe Kong","owner_url":"/insider/0001380841","role":"Officer (VP, Clinical Development)","officer_title":"VP, Clinical Development","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":1723.0,"shares_display":"1,723","price_per_share":6.035,"price_display":"6.04","price_state":"stated","total_value":10398.305,"total_display":"10,398.30","shares_owned_after":75362.0,"shares_owned_after_display":"75,362","ownership_form":"D","is_10b5_1":null,"transaction_date":"2008-05-15","filed_date":"2008-05-16","scope":"insider"},{"id":8273673,"accession":"0001142576-07-000020","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001142576-07-000020","line_url":"/filing/0001142576-07-000020#line-1","is_derivative":false,"issuer_cik":"0001142576","issuer_name":"OPTIMER PHARMACEUTICALS INC","issuer_ticker":"OPTR","issuer_name_source":null,"issuer_url":"/issuer/0001142576","owner_cik":"0001380841","owner_name":"Shue Youe Kong","owner_url":"/insider/0001380841","role":"Officer (VP Clinical Development)","officer_title":"VP Clinical Development","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":1000.0,"shares_display":"1,000","price_per_share":5.95,"price_display":"5.95","price_state":"stated","total_value":5950.0,"total_display":"5,950.00","shares_owned_after":75485.0,"shares_owned_after_display":"75,485","ownership_form":"D","is_10b5_1":null,"transaction_date":"2007-11-15","filed_date":"2007-11-19","scope":"insider"},{"id":7864983,"accession":"0001142576-07-000006","txn_seq":6,"anchor":"line-6","filing_url":"/filing/0001142576-07-000006","line_url":"/filing/0001142576-07-000006#line-6","is_derivative":false,"issuer_cik":"0001142576","issuer_name":"OPTIMER PHARMACEUTICALS INC","issuer_ticker":"OPTR","issuer_name_source":null,"issuer_url":"/issuer/0001142576","owner_cik":"0001380841","owner_name":"Shue Youe Kong","owner_url":"/insider/0001380841","role":"Officer (VP Clinical Development)","officer_title":"VP Clinical Development","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":1200.0,"shares_display":"1,200","price_per_share":8.3,"price_display":"8.30","price_state":"stated","total_value":9960.0,"total_display":"9,960.00","shares_owned_after":73685.0,"shares_owned_after_display":"73,685","ownership_form":"D","is_10b5_1":null,"transaction_date":"2007-08-10","filed_date":"2007-08-13","scope":"insider"},{"id":7864981,"accession":"0001142576-07-000006","txn_seq":5,"anchor":"line-5","filing_url":"/filing/0001142576-07-000006","line_url":"/filing/0001142576-07-000006#line-5","is_derivative":false,"issuer_cik":"0001142576","issuer_name":"OPTIMER PHARMACEUTICALS INC","issuer_ticker":"OPTR","issuer_name_source":null,"issuer_url":"/issuer/0001142576","owner_cik":"0001380841","owner_name":"Shue Youe Kong","owner_url":"/insider/0001380841","role":"Officer (VP Clinical Development)","officer_title":"VP Clinical Development","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":300.0,"shares_display":"300","price_per_share":8.24,"price_display":"8.24","price_state":"stated","total_value":2472.0,"total_display":"2,472.00","shares_owned_after":74485.0,"shares_owned_after_display":"74,485","ownership_form":"D","is_10b5_1":null,"transaction_date":"2007-08-10","filed_date":"2007-08-13","scope":"insider"},{"id":7864979,"accession":"0001142576-07-000006","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001142576-07-000006","line_url":"/filing/0001142576-07-000006#line-4","is_derivative":false,"issuer_cik":"0001142576","issuer_name":"OPTIMER PHARMACEUTICALS INC","issuer_ticker":"OPTR","issuer_name_source":null,"issuer_url":"/issuer/0001142576","owner_cik":"0001380841","owner_name":"Shue Youe Kong","owner_url":"/insider/0001380841","role":"Officer (VP Clinical Development)","officer_title":"VP Clinical Development","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":200.0,"shares_display":"200","price_per_share":8.29,"price_display":"8.29","price_state":"stated","total_value":1658.0,"total_display":"1,658.00","shares_owned_after":73885.0,"shares_owned_after_display":"73,885","ownership_form":"D","is_10b5_1":null,"transaction_date":"2007-08-10","filed_date":"2007-08-13","scope":"insider"},{"id":7864977,"accession":"0001142576-07-000006","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001142576-07-000006","line_url":"/filing/0001142576-07-000006#line-3","is_derivative":false,"issuer_cik":"0001142576","issuer_name":"OPTIMER PHARMACEUTICALS INC","issuer_ticker":"OPTR","issuer_name_source":null,"issuer_url":"/issuer/0001142576","owner_cik":"0001380841","owner_name":"Shue Youe Kong","owner_url":"/insider/0001380841","role":"Officer (VP Clinical Development)","officer_title":"VP Clinical Development","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":200.0,"shares_display":"200","price_per_share":8.27,"price_display":"8.27","price_state":"stated","total_value":1654.0,"total_display":"1,654.00","shares_owned_after":74185.0,"shares_owned_after_display":"74,185","ownership_form":"D","is_10b5_1":null,"transaction_date":"2007-08-10","filed_date":"2007-08-13","scope":"insider"},{"id":7864975,"accession":"0001142576-07-000006","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001142576-07-000006","line_url":"/filing/0001142576-07-000006#line-2","is_derivative":false,"issuer_cik":"0001142576","issuer_name":"OPTIMER PHARMACEUTICALS INC","issuer_ticker":"OPTR","issuer_name_source":null,"issuer_url":"/issuer/0001142576","owner_cik":"0001380841","owner_name":"Shue Youe Kong","owner_url":"/insider/0001380841","role":"Officer (VP Clinical Development)","officer_title":"VP Clinical Development","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":100.0,"shares_display":"100","price_per_share":8.28,"price_display":"8.28","price_state":"stated","total_value":828.0,"total_display":"828.00","shares_owned_after":73985.0,"shares_owned_after_display":"73,985","ownership_form":"D","is_10b5_1":null,"transaction_date":"2007-08-10","filed_date":"2007-08-13","scope":"insider"},{"id":7864973,"accession":"0001142576-07-000006","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001142576-07-000006","line_url":"/filing/0001142576-07-000006#line-1","is_derivative":false,"issuer_cik":"0001142576","issuer_name":"OPTIMER PHARMACEUTICALS INC","issuer_ticker":"OPTR","issuer_name_source":null,"issuer_url":"/issuer/0001142576","owner_cik":"0001380841","owner_name":"Shue Youe Kong","owner_url":"/insider/0001380841","role":"Officer (VP Clinical Development)","officer_title":"VP Clinical Development","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":500.0,"shares_display":"500","price_per_share":8.3,"price_display":"8.30","price_state":"stated","total_value":4150.0,"total_display":"4,150.00","shares_owned_after":72485.0,"shares_owned_after_display":"72,485","ownership_form":"D","is_10b5_1":null,"transaction_date":"2007-08-09","filed_date":"2007-08-13","scope":"insider"}],"next_cursor":null,"ledger_fault":false,"count":{"value":13,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":13,"open_market":true},{"code":"S","label":"Open-market sale","n":0,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":13},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001142576","name":"OPTIMER PHARMACEUTICALS INC","url":"/issuer/0001142576","role":"Officer (VP, Clinical Development)","n_filings":5,"first_seen":"2007-08-13","last_seen":"2009-12-02"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001380841","retrieved_at":"2026-08-21T07:02:53+00:00","coverage":{"filings":1505395,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-20","last_ingest":"2026-08-21T05:23:33.898496+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}